Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners

Luca Iaccarino; Rosaria Talarico; Emanuele Bozzalla-Cassione; Gerd R. Burmester; Emma L. Culver; Andrea Doria; Mikael Ebbo; P. Martin van Hagen; Eric Hachulla; Jan A.M. van Laar; Marco Lanzillotta; Fernando Martinez-Valle; Carlomaurizio Montecucco; Sara Monti; Cecilia Nalli; Nicolas Schleinitz; Angela Tincani; Emanuel Della-Torre; Tobias Alexander

doi:10.55563/clinexprheumatol/qq9qup

Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners

Luca Iaccarino, Rosaria Talarico, Emanuele Bozzalla-Cassione, Gerd R. Burmester, Emma L. Culver, Andrea Doria, Mikael Ebbo, P. Martin van Hagen, Eric Hachulla, Jan A.M. van Laar, Marco Lanzillotta, Fernando Martinez-Valle, Carlomaurizio Montecucco, Sara Monti, Cecilia Nalli, Nicolas Schleinitz, Angela Tincani, Emanuel Della-Torre, Tobias Alexander^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

10 Citations (Scopus)

Abstract

Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a chronic, clinically heterogenous fibroinflammatory condition, characterised by an accumulation of IgG4 secreting plasma cells in affected tissues and associated with increased serum IgG4 concentrations. Despite a growing recognition of the disease among clinicians from different specialties worldwide, its indolent nature, lack of a single diagnostic test and ability to mimic other malignant, infective and inflammatory conditions, makes the diagnosis challenging. As treatment options evolve, biomarkers correlating with disease activity, predicting prognosis and response to treatment are deemed required. A multidisciplinary panel of experts from the European Reference Network for Rare and Complex Connective tissue diseases (ERN ReCONNET) and affiliated international partners have performed a narrative literature search and reviewed the current evidence of biomarkers in IgG4-RD, including immunoglobulins, cytokines, chemokines and other soluble immune mediators, and cellular components of the immune system. The aim of this paper is to provide useful information for clinicians as to the utility of biomarkers for diagnosing and monitoring IgG4-RD in clinical routine and sets out recommendations for clinical decision making.

Original language	English
Pages (from-to)	S71-S80
Journal	Clinical and Experimental Rheumatology
Volume	40
Issue number	5
DOIs	https://doi.org/10.55563/clinexprheumatol/qq9qup
Publication status	Published - May 2022

Bibliographical note

This publication was funded by the European Union’s Health Programme (2014-2020).
ERN ReCONNET is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member
States. The ERNs are co-funded by the EC (European Commission). The content of this publication represents
the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the
EC and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union.
The EC and HaDEA do not accept any responsibility for use that may be made of the information it contains.

Publisher Copyright: © 2022 Clinical and Experimental Rheumatology S.A.S.. All rights reserved.

Access to Document

10.55563/clinexprheumatol/qq9qup

Cite this

Iaccarino, L., Talarico, R., Bozzalla-Cassione, E., Burmester, G. R., Culver, E. L., Doria, A., Ebbo, M., van Hagen, P. M., Hachulla, E., van Laar, J. A. M., Lanzillotta, M., Martinez-Valle, F., Montecucco, C., Monti, S., Nalli, C., Schleinitz, N., Tincani, A., Della-Torre, E., & Alexander, T. (2022). Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners. Clinical and Experimental Rheumatology, 40(5), S71-S80. https://doi.org/10.55563/clinexprheumatol/qq9qup

@article{776b29952e6a4ec189114c0240a7930c,

title = "Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners",

abstract = "Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a chronic, clinically heterogenous fibroinflammatory condition, characterised by an accumulation of IgG4 secreting plasma cells in affected tissues and associated with increased serum IgG4 concentrations. Despite a growing recognition of the disease among clinicians from different specialties worldwide, its indolent nature, lack of a single diagnostic test and ability to mimic other malignant, infective and inflammatory conditions, makes the diagnosis challenging. As treatment options evolve, biomarkers correlating with disease activity, predicting prognosis and response to treatment are deemed required. A multidisciplinary panel of experts from the European Reference Network for Rare and Complex Connective tissue diseases (ERN ReCONNET) and affiliated international partners have performed a narrative literature search and reviewed the current evidence of biomarkers in IgG4-RD, including immunoglobulins, cytokines, chemokines and other soluble immune mediators, and cellular components of the immune system. The aim of this paper is to provide useful information for clinicians as to the utility of biomarkers for diagnosing and monitoring IgG4-RD in clinical routine and sets out recommendations for clinical decision making.",

author = "Luca Iaccarino and Rosaria Talarico and Emanuele Bozzalla-Cassione and Burmester, {Gerd R.} and Culver, {Emma L.} and Andrea Doria and Mikael Ebbo and {van Hagen}, {P. Martin} and Eric Hachulla and {van Laar}, {Jan A.M.} and Marco Lanzillotta and Fernando Martinez-Valle and Carlomaurizio Montecucco and Sara Monti and Cecilia Nalli and Nicolas Schleinitz and Angela Tincani and Emanuel Della-Torre and Tobias Alexander",

note = "This publication was funded by the European Union{\textquoteright}s Health Programme (2014-2020). ERN ReCONNET is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the EC (European Commission). The content of this publication represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the EC and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The EC and HaDEA do not accept any responsibility for use that may be made of the information it contains. Publisher Copyright: {\textcopyright} 2022 Clinical and Experimental Rheumatology S.A.S.. All rights reserved.",

year = "2022",

month = may,

doi = "10.55563/clinexprheumatol/qq9qup",

language = "English",

volume = "40",

pages = "S71--S80",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology S.A.S.",

number = "5",

}

Iaccarino, L, Talarico, R, Bozzalla-Cassione, E, Burmester, GR, Culver, EL, Doria, A, Ebbo, M, van Hagen, PM, Hachulla, E, van Laar, JAM, Lanzillotta, M, Martinez-Valle, F, Montecucco, C, Monti, S, Nalli, C, Schleinitz, N, Tincani, A, Della-Torre, E & Alexander, T 2022, 'Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners', Clinical and Experimental Rheumatology, vol. 40, no. 5, pp. S71-S80. https://doi.org/10.55563/clinexprheumatol/qq9qup

Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners. / Iaccarino, Luca; Talarico, Rosaria; Bozzalla-Cassione, Emanuele et al.
In: Clinical and Experimental Rheumatology, Vol. 40, No. 5, 05.2022, p. S71-S80.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners

AU - Iaccarino, Luca

AU - Talarico, Rosaria

AU - Bozzalla-Cassione, Emanuele

AU - Burmester, Gerd R.

AU - Culver, Emma L.

AU - Doria, Andrea

AU - Ebbo, Mikael

AU - van Hagen, P. Martin

AU - Hachulla, Eric

AU - van Laar, Jan A.M.

AU - Lanzillotta, Marco

AU - Martinez-Valle, Fernando

AU - Montecucco, Carlomaurizio

AU - Monti, Sara

AU - Nalli, Cecilia

AU - Schleinitz, Nicolas

AU - Tincani, Angela

AU - Della-Torre, Emanuel

AU - Alexander, Tobias

N1 - This publication was funded by the European Union’s Health Programme (2014-2020). ERN ReCONNET is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the EC (European Commission). The content of this publication represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the EC and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The EC and HaDEA do not accept any responsibility for use that may be made of the information it contains. Publisher Copyright: © 2022 Clinical and Experimental Rheumatology S.A.S.. All rights reserved.

PY - 2022/5

Y1 - 2022/5

N2 - Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a chronic, clinically heterogenous fibroinflammatory condition, characterised by an accumulation of IgG4 secreting plasma cells in affected tissues and associated with increased serum IgG4 concentrations. Despite a growing recognition of the disease among clinicians from different specialties worldwide, its indolent nature, lack of a single diagnostic test and ability to mimic other malignant, infective and inflammatory conditions, makes the diagnosis challenging. As treatment options evolve, biomarkers correlating with disease activity, predicting prognosis and response to treatment are deemed required. A multidisciplinary panel of experts from the European Reference Network for Rare and Complex Connective tissue diseases (ERN ReCONNET) and affiliated international partners have performed a narrative literature search and reviewed the current evidence of biomarkers in IgG4-RD, including immunoglobulins, cytokines, chemokines and other soluble immune mediators, and cellular components of the immune system. The aim of this paper is to provide useful information for clinicians as to the utility of biomarkers for diagnosing and monitoring IgG4-RD in clinical routine and sets out recommendations for clinical decision making.

AB - Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a chronic, clinically heterogenous fibroinflammatory condition, characterised by an accumulation of IgG4 secreting plasma cells in affected tissues and associated with increased serum IgG4 concentrations. Despite a growing recognition of the disease among clinicians from different specialties worldwide, its indolent nature, lack of a single diagnostic test and ability to mimic other malignant, infective and inflammatory conditions, makes the diagnosis challenging. As treatment options evolve, biomarkers correlating with disease activity, predicting prognosis and response to treatment are deemed required. A multidisciplinary panel of experts from the European Reference Network for Rare and Complex Connective tissue diseases (ERN ReCONNET) and affiliated international partners have performed a narrative literature search and reviewed the current evidence of biomarkers in IgG4-RD, including immunoglobulins, cytokines, chemokines and other soluble immune mediators, and cellular components of the immune system. The aim of this paper is to provide useful information for clinicians as to the utility of biomarkers for diagnosing and monitoring IgG4-RD in clinical routine and sets out recommendations for clinical decision making.

UR - http://www.scopus.com/inward/record.url?scp=85130768004&partnerID=8YFLogxK

U2 - 10.55563/clinexprheumatol/qq9qup

DO - 10.55563/clinexprheumatol/qq9qup

M3 - Review article

C2 - 35238758

AN - SCOPUS:85130768004

SN - 0392-856X

VL - 40

SP - S71-S80

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 5

ER -

Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this